RxDoctor Payments Data

Michael Overdahl, MD

Pulmonary Disease · Fort Wayne, INNPI 1316990112

Payments from drug & device makers

$358in general payments, 2019–2025

Across 18 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$112
  • Amgen$70
  • Genentech USA, Inc.$48
  • Inogen, Inc.$46
  • Regeneron Healthcare Solutions, Inc.$24
  • Sanofi$21
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$31087%
  • Education$4813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358 in reported general payments places this provider in the 20th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$49,529
Medicare patients
252
Services billed
778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter649$515,360
OfevNintedanib Esylate28$280,016
Breo ElliptaFluticasone/Vilanterol399$220,340
Pirfenidone27$82,289
Breztri AerosphereBudesonide/Glycopyr/Formoterol67$57,023
Spiriva HandihalerTiotropium Bromide33$31,666
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$28,692
SymbicortBudesonide/Formoterol Fumarate72$25,352
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$19,928
Spiriva RespimatTiotropium Bromide23$15,964
Combivent RespimatIpratropium/Albuterol Sulfate26$12,428
Incruse ElliptaUmeclidinium Bromide15$8,863
DuleraMometasone/Formoterol20$8,243
Albuterol Sulfate HfaAlbuterol Sulfate375$8,018
Arnuity ElliptaFluticasone Furoate26$7,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$112$780,3361,142 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$20$328,33797 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →